Management of Respiratory Failure or ARDS In COVID Patients

Acute respiratory distress syndrome (ARDS) is one of the most serious complications associated with a higher risk of mortality in COVID-19 patients. It can originate from the vascular or gas side of the alveoli.

Although the site of entry or spread of COVID-19 is inhalational, alveolar infiltrates have been commonly found in the chest x-rays or computed tomography scans of patients with this infection. Respiratory distress also appears to include vascular damage that can potentially mandate a unique treatment approach other than what is recommended for patients who have developed ARDS due to other causes.

Also, a wide variation in the mortality rate has been observed across different intensive care units. This further raises the possibility that the differences in the approach to ventilatory management could be a factor contributing to the varying outcomes.

We are going to discuss this in detail in our ‘COVID19 PANDEMIC BY EXPERTS IN THE FIELD WEBINAR’ on 4th November.  Our webinar is focused on providing information about the latest developments in COVID-19 including the management of ARDS and short-term and long-term complications this infection can cause. You can join the webinar to keep yourself updated about the management of respiratory distress in COVID-19 patients.

Research studies have shown that the impact of COVID-19 is not limited to the lungs. It is a systemic disorder that can also injure the vascular endothelium. If not managed expertly and individually with consideration of its vasocentric features, it would not just increase the risk of ARDS but also lead to multiorgan failure, even in patients who are young or middle-aged without any pre-existing comorbidity.

Researchers have revealed that ARDS may also develop faster in COVID-19 patients due to the disproportionate endothelial damage that causes disruptions in the pulmonary vasoregulation, and ventilation-perfusion mismatch. This may lead to initial hypoxemia and foster thrombogenesis.

This might be in contrast to the pathogenesis of ARDS developed due to causes other than COVID-19. This marks the need to learn how respiratory distress needs to be managed differently and with a unique approach in COVID patients.

You can join the ‘COVID19 PANDEMIC BY EXPERTS IN THE FIELD WEBINAR’ on 4th November between 3 pm to 8 pm to learn more about the management of ARDS. We will discuss respiratory therapy CEU’s and why the approach needs to be modified in COVID-19 patients to improve the chances of positive outcomes.

We will also discuss the evolution and epidemiology of the COVID pandemic and how this infection can create havoc in the patient's body by creating complications.

We will share with you a clinician’s view from inside a COVID ICU to help physicians and nurses prepare themselves to face the challenges. This webinar also includes a discussion about the future of COVID-19 in view of treatments, vaccinations, and the development of herd immunity.

You will get an opportunity to interact with and ask questions to our panel of expert physicians. Join the respiratory conference to keep yourself updated about COVID-19 and improve your expertise in the management of this infection. 

Popular posts from this blog

RESPIRATORY THERAPY TOPICS ON SLEEP MEDICINE WEBINAR

A & T Lectures Sleep Medicine Webinar Respiratory Conference that is considered live or traditional CEU’s. You can interact and ask questions after the presentation. Hosted by A & T Lectures Using Zoom Video Communications We will be offering 5 Live/Webinar AARC approved CEU’s October 22 @ 4:00 pm - 9:00 pm  CONFERENCE SCHEDULE AND INSTRUCTION ON ACCESSING THIS WEBINAR Register for the conference Special note: You can join the conference for free but only those that register will get the 5 CEU’s Download ZOOM to your computer or laptop/desktop (its free) Practice using ZOOM with a friend before entering the webinar as this will not be the right time to teach you how to access the conference Make sure you join the webinar by accessing this link 10 minutes before the conference. Join The Webinar
Read more

Pulmonary Fibrosis – Symptoms, Causes, Stages, and Treatment

Image
Pulmonary fibrosis is a lung disorder that occurs when the tissues in the lungs become damaged followed by scarring. Scaring results in the formation of thick and stiff tissue that makes it more difficult for the lungs to expand and relax preventing them from working properly. As pulmonary fibrosis becomes worsens, the patient becomes short of breath in a progressive manner. The scarring linked to pulmonary fibrosis is often caused due to a combination of factors. However, in most cases, it is difficult to detect the exact cause that triggered the development of this condition. When no specific cause can be found, the condition is called idiopathic pulmonary fibrosis. The damage caused due to pulmonary fibrosis cannot be reversed. However, medications and treatment may sometimes help to ease the symptoms and improve the patient's quality of life. In some patients, a lung transplant may be required. Stages of pulmonary fibrosis Stage 1: Recent diagnosis The common early
Read more

Management Of Respiratory Failure In COVID Patients

Image
Management Of Respiratory Failure In COVID Patients It’s been more than 8 months now and still, the COVID-19 pandemic shows no sign of decline in the number of cases. What makes the COVID-19 pandemic a major cause of concern is the high risk of mortality associated with it, particularly due to respiratory failure. COVID-19 has a higher tropism for the lung and is known to cause severe pneumonia and ARDS (acute respiratory distress syndrome), especially in patients with a weak immune system and existing co-morbidities. This marks the need for the physicians, nurses, and healthcare workers to stay abreast of the latest information about the risk of ARDS and the recommended protocol for the management of respiratory distress in COVID-19 patients. Clinical features of ARDS in COVID-19 patents Most patients with COVID-induced respiratory distress meet the Berlin definition of ARDS. However, some patients may exhibit a different phenotype of ARDS with lower lung weight, higher lu
Read more